entertainment -WSS

entertainment

author：leisure time 2025-10-01 06:01:11 - browse：8

Who polices algorithms? How would you name the first approved CRISPR medicine? And what pairs well with a biotech downturn?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Casey Ross joins us to tell the bombshell story of how the nation’s largest health insurer used a computer algorithm to deny patient care and boost its profitability. Then, biotech veteran Michael Gilman calls in to offer a behind-the-scenes peek at what it’s like to be a startup CEO in this economic downturn — and which cocktail recipes help make it bearable. We also discuss a pioneering approval for a genome-editing medicine.

For more on what we cover, here’s the UnitedHealth story; here’s more on the CRISPR approval; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

entertainment

WSS

Biogen walks away from Aduhelm, years after polarizing approval

Bernie Sanders is gearing up to subpoena pharma CEOs

New clues to why women have higher risk of autoimmune disorders

ADCs take center stage as promising cancer treatments

Medicare Advantage insurers face 0.2% cut to 2025 payments

Readout Newsletter: The latest on Novavax, Merck, Bluebird

leisure time

entertainment

knowledge

Alkermes shareholders re

Cassava Sciences’ Alzheimer’s clinical trials should be halted

BioMarin wins approval for gene therapy to treat hemophilia A

Roche drug slashes death risk in early

State Dept. review finds Biden bears some blame for Afghanistan failures

Results on Novartis prostate cancer therapy could expand its use

Psychedelics group wrestles with new pharma identity

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

ChatGPT in medicine: STAT answers readers' burning questions

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

focus

Readout LOUD podcast: Live from the 2023 STAT Summit

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Readout Newsletter: The latest on Novavax, Merck, Bluebird

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Venture capital firm's plans to take over Akron hospital face hurdles

Is there really a nursing shortage in the U.S.?

knowledge

hotspot

entertainment

leisure time